IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
IO Biotech (Nasdaq: IOBT) announced that an abstract on their lead therapeutic cancer vaccine candidate, IO102-IO103, has been accepted for poster presentation at the ESMO Congress 2024. The presentation will showcase data from a completed cohort of squamous cell carcinoma of the head and neck (SCCHN) patients in a Phase 2 basket trial combining IO102-IO103 with pembrolizumab.
The poster, titled 'A phase 2 trial of the IO102-IO103 vaccine plus pembrolizumab: completed cohort for first line (1L) treatment of advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)', will be presented on September 14, 2024, at the congress in Barcelona. This data represents a significant step in exploring IO102-IO103's potential across various solid tumors with high unmet medical needs.
IO Biotech (Nasdaq: IOBT) ha annunciato che un abstract sul loro principale candidato vaccinale terapeutico contro il cancro, IO102-IO103, è stato accettato per una presentazione poster al Congresso ESMO 2024. La presentazione mostrerà dati da una coorte completata di pazienti con carcinoma a cellule squamose della testa e del collo (SCCHN) in uno studio di fase 2 che combina IO102-IO103 con pembrolizumab.
Il poster, intitolato 'Uno studio di fase 2 del vaccino IO102-IO103 più pembrolizumab: coorte completata per il trattamento di prima linea (1L) del carcinoma avanzato a cellule squamose della testa e del collo (SCCHN)', sarà presentato il 14 settembre 2024, al congresso di Barcellona. Questi dati rappresentano un passo significativo nell'esplorazione del potenziale di IO102-IO103 in vari tumori solidi con elevate esigenze mediche non soddisfatte.
IO Biotech (Nasdaq: IOBT) anunció que un resumen sobre su principal candidato a vacuna terapéutica contra el cáncer, IO102-IO103, ha sido aceptado para presentación de póster en el Congreso ESMO 2024. La presentación mostrará datos de una cohorte completada de pacientes con carcinoma de células escamosas de cabeza y cuello (SCCHN) en un ensayo de fase 2 que combina IO102-IO103 con pembrolizumab.
El póster, titulado 'Un ensayo de fase 2 de la vacuna IO102-IO103 más pembrolizumab: cohorte completada para el tratamiento de primera línea (1L) del carcinoma escamoso avanzado de cabeza y cuello (SCCHN)', se presentará el 14 de septiembre de 2024, en el congreso en Barcelona. Estos datos representan un paso significativo en la exploración del potencial de IO102-IO103 en varios tumores sólidos con altas necesidades médicas no satisfechas.
IO Biotech(Nasdaq: IOBT)는 그들의 주요 치료 암 백신 후보인 IO102-IO103에 대한 초록이 ESMO Congress 2024에서 포스터 발표로 채택되었다고 발표했습니다. 이 발표는 IO102-IO103을 펨브롤리주맙과 결합한 2상 바구니 시험에서 완료된 두경부 편평세포암(SCCHN) 환자 군의 데이터를 보여줄 것입니다.
위 제목의 포스터 'IO102-IO103 백신과 펨브롤리주맙의 2상 시험: 진행성 두경부 편평세포암(SCCHN)의 1차 치료(1L)를 위한 완료된 환자군'은 2024년 9월 14일 바르셀로나에서 열리는 학회에서 발표될 예정입니다. 이 데이터는 IO102-IO103의 잠재력을 다양한 높은 의료 미충족 요구를 가진 고형 종양에 대해 탐색하는 중요한 단계를 나타냅니다.
IO Biotech (Nasdaq: IOBT) a annoncé qu'un résumé sur leur principal candidat vaccin thérapeutique contre le cancer, IO102-IO103, a été accepté pour une présentation sous forme de poster au Congrès ESMO 2024. La présentation mettra en avant des données d'une cohorte terminée de patients atteints de carcinome à cellules squameuses de la tête et du cou (SCCHN) dans un essai de phase 2 combinant IO102-IO103 avec du pembrolizumab.
Le poster, intitulé 'Un essai de phase 2 du vaccin IO102-IO103 plus pembrolizumab : cohorte terminée pour le traitement de première ligne (1L) du carcinome avancé à cellules squameuses de la tête et du cou (SCCHN)', sera présenté le 14 septembre 2024, lors du congrès à Barcelone. Ces données représentent une étape significative dans l'exploration du potentiel d'IO102-IO103 dans divers tumeurs solides avec des besoins médicaux non satisfaits élevés.
IO Biotech (Nasdaq: IOBT) gab bekannt, dass ein Abstract über ihren führenden therapeutischen Impfstoffkandidaten gegen Krebs, IO102-IO103, zur Posterpräsentation auf dem ESMO Congress 2024 angenommen wurde. Die Präsentation wird Daten aus einer abgeschlossenen Kohorte von Patienten mit Plattenepithelkarzinom des Kopfes und Halses (SCCHN) aus einer Phase-2-Studie zeigen, die IO102-IO103 mit Pembrolizumab kombiniert.
Das Poster mit dem Titel 'Eine Phase-2-Studie des IO102-IO103-Impfstoffs plus Pembrolizumab: abgeschlossene Kohorte für die Erstlinientherapie (1L) von fortgeschrittenem Plattenepithelkarzinom des Kopfes und Halses (SCCHN)' wird am 14. September 2024 auf dem Kongress in Barcelona präsentiert. Diese Daten stellen einen bedeutenden Schritt dar, um das Potenzial von IO102-IO103 bei verschiedenen soliden Tumoren mit hohen unerfüllten medizinischen Bedürfnissen zu erkunden.
- Abstract accepted for poster presentation at ESMO Congress 2024
- Completed cohort data for SCCHN in Phase 2 trial to be presented
- Potential advancement in treatment for solid tumors with high unmet needs
- None.
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The poster will share data from one of the Phase 2 basket trials of IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy. The data for the complete squamous cell carcinoma of the head and neck (SCCHN) cohort of the IOB-022/KN-D38 study will be presented at the Congress, which takes place in Barcelona from September 13-17, 2024.
“This completed cohort data marks a significant step forward in our efforts to explore the potential of IO102-IO103 as a therapeutic cancer vaccine across a range of solid tumors where there is a high need for new, accessible treatments,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech. “We look forward to the presentation of this data at the upcoming ESMO Congress and the continued development of our novel immune-modulating cancer vaccine that could potentially improve outcomes for people living with cancer.”
Presentation Details
Title: A phase 2 trial of the IO102-IO103 vaccine plus pembrolizumab: completed cohort for first line (1L) treatment of advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Presentation date: Saturday, September 14, 2024
Presenter: Jonathan W. Riess, MD MS (UC Davis Comprehensive Cancer Center)
Presentation number: 1022P
The poster will be available on the “Posters & Publications” page of the IO Biotech website at the start of the meeting.
About IO102-IO103
IO102-IO103 is an investigational off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase (IDO) positive and/or programmed death-ligand 1 (PD-L1) positive cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating IO102-IO103 in combination with pembrolizumab as first line treatment in patients with solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating IO102-IO103 in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors.
The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
About IOB-022/KN-D38 Phase 2 Solid Tumor Basket Trial
IOB-022/KN-D38 (NCT05077709) is a non-comparative, open label trial to investigate the safety and efficacy of IO102-IO103 in combination with pembrolizumab in first-line advanced cancers in non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN). IO Biotech is sponsoring the Phase 2 trial and Merck is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target the immunosuppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, IO102-IO103, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with pembrolizumab, has been granted a breakthrough therapy designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing of the primary analysis of the company’s Phase 3 trial, current or future clinical trials, their progress, enrollment or results, timing of submission of marketing applications, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Contact:
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
FAQ
What is IO Biotech's stock symbol?
What is IO102-IO103?
When and where will IO Biotech present their SCCHN cohort data?
What type of cancer is being studied in the presented cohort?
Who will present the IO Biotech poster at ESMO 2024?
